Evidence map›Paper›PMID 30178158›Full record

ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2018

Bone management in hematologic stem cell transplant recipients.

D L Kendler, J J Body, M L Brandi, R Broady, J Cannata-Andia, M J Cannata-Ortiz, A El Maghraoui, G Guglielmi, P Hadji, D D Pierroz and 4 more

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Increased risk of hip and major osteoporotic fractures in 8463 patients who have undergone stem cell transplantation, a Swedish population-based study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Bone loss induced by cancer treatments in breast and prostate cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 9 countries.

D L KendlerDepartment of Medicine, Division of Endocrinology, University of British Columbia, 150 - 943 W. Broadway, Vancouver, V5Z 4E1, Canada. davidkendler@gmail.com.
J J BodyCHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
M L BrandiMineral and Bone Metabolic Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
R BroadyDepartment of Medicine, Division of Hematology, University of British Columbia, Vancouver, Canada.
J Cannata-AndiaServicio de Metabolismo Óseo y Mineral, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain.
M J Cannata-OrtizHaematology Department, IIS Princesa, Hospital de la Princesa, Madrid, Spain.
A El MaghraouiRheumatology Department, Military Hospital Mohammed V, Mohammed V-Souissi University, Rabat, Morocco.
G GuglielmiDepartment of Radiology, University of Foggia, Foggia, Italy.
P HadjiDepartment of Bone Oncology, Endocrinology and Reproductive Medicine, Nord West Hospital, Frankfurt, Germany.
D D PierrozInternational Osteoporosis Foundation (IOF), Nyon, Switzerland.
T J de VilliersDepartment of Gynaecology, Faculty of Health Sciences, Stellenbosch University, Stellenbosch, South Africa.
R RizzoliDivision of Bone Diseases, Faculty of Medicine, Geneva University Hospital, Geneva, Switzerland.
P R EbelingDepartment of Medicine, School of Clinical Sciences, Monash University, Clayton, Australia.
International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer and Bone Disease
University of British Columbia · CAHospital Universitario Central de Asturias · ESHospital Universitario de La Princesa · ESKrankenhaus Nordwest · DEMohammed V University · MAMonash University · AUStellenbosch University · ZAUniversité Libre de Bruxelles · BEUniversity Hospital of Geneva · CHUniversity of Florence · ITUniversity of Foggia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for patients with some malignant and non-malignant hematological diseases. Advances in transplantation techniques and supportive care measures have substantially increased the number of long-term HSCT survivors. This has led to an increasing patient population suffering from the late effects of HSCT, of which, bone loss and its consequent fragility fractures lead to substantial morbidity. Altered bone health, with consequent fragility fractures, and chronic graft-versus-host disease (GVHD) are factors affecting long-term quality of life after HSCT. Hypogonadism, HSCT preparative regimens, nutritional factors, and glucocorticoids all contribute to accelerated bone loss and increased fracture risk. Management strategies should include bone mineral density examination, evaluation of clinical risk factors, and general dietary and physical activity measures. Evidence has accumulated permitting recommendations for more attentiveness to evaluation and monitoring of bone health, with appropriate application of osteoporosis pharmacotherapies to patients at increased risk of bone loss and fracture.

Indexed as

Bone Density Conservation AgentsCalcineurin InhibitorsGlucocorticoidsHematopoietic Stem Cell TransplantationHumansOsteoporosisOsteoporotic FracturesPractice Guidelines as TopicRisk FactorsBone Density Conservation AgentsCalcineurin InhibitorsGlucocorticoidsBone lossBone marrowBone mineral densityFractureHematopoietic stem cellTransplantation

Identifiers

PMID30178158
OpenAlexW2890336699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.